Undisclosed CAR-T Program(s)
Hematological Malignancies (e.g., NHL, ALL, Myeloma)
Phase 1Active
Key Facts
Indication
Hematological Malignancies (e.g., NHL, ALL, Myeloma)
Phase
Phase 1
Status
Active
Company
About TriArm Therapeutics
TriArm Therapeutics is a private, clinical-stage biotechnology company founded in 2019 and headquartered in New York, USA. The company is developing a pipeline of CAR-T cell therapies using its core non-viral platform, which aims to improve safety profiles, reduce manufacturing complexity, and lower costs compared to current approved CAR-T products. This strategy targets a significant unmet need by making these potentially curative treatments accessible to a broader global patient population, including those in emerging markets. As a pre-revenue company, TriArm is executing on its clinical programs to validate its platform and attract potential partnerships or further investment.
View full company profile